129504-97-8

Upstream product

• 536-90-3 m-Anisidine 
• 1710-98-1 p-tert-butyl benzoyl chloride 

Downstream Products

• 1026640-82-3 {2-[5-(4-tert-butyl-phenyl)-4-(3-methoxy-phenyl)-4H-[1,2,4]triazol-3-yl]-ethyl}-dimethyl-amine 
• 581814-71-3 1-{3-[4-(tert-butyl)phenyl]-5-N,N-dimethylaminomethyl-(1,2,4-triazol-4-yl)}-3-methoxylbenzene 
• 581814-69-9 1-{3-[4-(tert-butyl)phenyl]-5-N,N-dimethylamino-(1,2,4-triazol-4-yl)}-3-methoxylbenzene 
• 581814-74-6 C₁₈H₂₃N₃O 
• 581814-63-3 1-{3-[4-(tert-butyl)-phenyl]-(1,2,4-triazol-4-yl)}-3-methoxybenzene 
• 581814-73-5 4-tert-butyl-N-(3-methoxyphenyl)thiobenzamide 

Relevant academic research and scientific papers

Discovery of novel triazole-based opioid receptor antagonists

We report the computer-aided design, chemical synthesis, and biological evaluation of a novel family of δ opioid receptor (DOR) antagonists containing a 1,2,4-triazole core structure that are structurally distinct from other known opioid receptor active l

OPIOID RECEPTOR ACTIVE COMPOUNDS

The invention provides compounds of formula I: wherein R1 to R4 and n have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic methods for treating pain and treating other conditions which involve, for example, binding opioid receptors using compounds of formula I.